Literature DB >> 1384676

Whole-arm t(1;16) and i(1q) as sole anomalies identify gain of 1q as a primary chromosomal abnormality in breast cancer.

N Pandis1, S Heim, G Bardi, I Idvall, N Mandahl, F Mitelman.   

Abstract

Cytogenetic analysis of four ductal breast carcinomas revealed net gain of 1q in all tumors. In the first tumor, the only change was that one chromosome 16 was replaced by a derivative chromosome consisting of 16p and 1q. The same unbalanced whole-arm translocation was also found in the second tumor, as the only aberration in one of four abnormal clones. In the last two cases, which also were characterized by cytogenetically unrelated clones, an extra i(1q) was present in one clone in both tumors as the sole aberration. Our findings suggest that gain of 1q is a primary chromosomal abnormality in breast carcinomas, in the sense that it is an early event that precedes the acquisition of more complex changes.

Entities:  

Mesh:

Year:  1992        PMID: 1384676     DOI: 10.1002/gcc.2870050310

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  13 in total

1.  Detection of numerical and structural alterations and fusion of chromosomes 16 and 1 in low-grade papillary breast carcinoma by fluorescence in situ hybridization.

Authors:  H Tsuda; T Takarabe; N Susumu; J Inazawa; S Okada; S Hirohashi
Journal:  Am J Pathol       Date:  1997-10       Impact factor: 4.307

2.  Additional chromosome 1q aberrations and der(16)t(1;16), correlation to the phenotypic expression and clinical behavior of the Ewing family of tumors.

Authors:  B Stark; C Mor; M Jeison; R Gobuzov; I J Cohen; Y Goshen; J Stein; S Fisher; S Ash; I Yaniv; R Zaizov
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

3.  Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization.

Authors:  A Kallioniemi; O P Kallioniemi; J Piper; M Tanner; T Stokke; L Chen; H S Smith; D Pinkel; J W Gray; F M Waldman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

4.  Overexpression of S100A4 in human cancer cell lines resistant to methotrexate.

Authors:  Nuria Mencía; Elisabet Selga; Isabel Rico; M Cristina de Almagro; Xenia Villalobos; Sara Ramirez; Jaume Adan; Jose L Hernández; Véronique Noé; Carlos J Ciudad
Journal:  BMC Cancer       Date:  2010-06-01       Impact factor: 4.430

5.  Frequent 7q gains in flow cytometric multiploid/hypertetraploid breast carcinomas: a study of chromosome imbalances by comparative genomic hybridisation.

Authors:  A E Pinto; L Roque; R Rodrigues; S André; J Soares
Journal:  J Clin Pathol       Date:  2006-02-03       Impact factor: 3.411

6.  WWOX, the common chromosomal fragile site, FRA16D, cancer gene.

Authors:  J H Ludes-Meyers; A K Bednarek; N C Popescu; M Bedford; C M Aldaz
Journal:  Cytogenet Genome Res       Date:  2003       Impact factor: 1.636

7.  Increased copy number at 3p14 in breast cancer.

Authors:  Ingrid Ljuslinder; Beatrice Malmer; Irina Golovleva; Marcus Thomasson; Kjell Grankvist; Thomas Höckenström; Stefan Emdin; Yvonne Jonsson; Håkan Hedman; Roger Henriksson
Journal:  Breast Cancer Res       Date:  2005-07-06       Impact factor: 6.466

8.  Pericentromeric regions are refractory to prompt repair after replication stress-induced breakage in HPV16 E6E7-expressing epithelial cells.

Authors:  Wen Deng; Sai Wah Tsao; Xin-Yuan Guan; Annie L M Cheung
Journal:  PLoS One       Date:  2012-10-31       Impact factor: 3.240

9.  Karyotypic abnormalities in tumours of the pancreas.

Authors:  G Bardi; B Johansson; N Pandis; N Mandahl; E Bak-Jensen; A Andrén-Sandberg; F Mitelman; S Heim
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

10.  Cytogenetic analysis of multifocal breast carcinomas: detection of karyotypically unrelated clones as well as clonal similarities between tumour foci.

Authors:  M R Teixeira; N Pandis; G Bardi; J A Andersen; N Mandahl; F Mitelman; S Heim
Journal:  Br J Cancer       Date:  1994-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.